ESMO - Eur. Oncology· @myESMO · X·· 15 小时前评分70
正文 · 原文
#ESMO26: Intismeran autogene individualised #mRNA-based #NeoantigenVaccine therapy reduced recurrence risk by 42% in patients with resectable #melanoma treated with adjuvant pembrolizumab in the INTerpath-001 phase III #ClinicalTrial
🔗 https://ow.ly/a6FC50ZZkJV
#InsightsbyESMO
582 浏览 · 9 赞 · 3 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com